Evidence map›Paper›PMID 39619481›Full record

ArticleGenes & diseases2025

TULP4 degrades RYBP to enhance DNA damage repair and chemosensitivity of pancreatic ductal adenocarcinoma.

Jingyao Dai, Su Liu, Yangyang Xie, Yixuan Wang, Xiyun Bian, Tian Yu, Tiantian Li, Linchuang Jia, Zhigang Zhao, Zhiqiang Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingyao DaiHepatobiliary Surgery Department, Air Force Medical Center, Beijing 100142, China.
Su LiuTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Yangyang XieDepartment of Pathophysiology, School of Basic Medical Science, Tianjin Medical University, Tianjin 300060, China.
Yixuan WangDepartment of Pathophysiology, School of Basic Medical Science, Tianjin Medical University, Tianjin 300060, China.
Xiyun BianTianjin Key Laboratory of Epigenetics for Organ Development in Preterm Infants, Tianjin Fifth Central Hospital, Tianjin 300450, China.
Tian YuTianjin Key Laboratory of Epigenetics for Organ Development in Preterm Infants, Tianjin Fifth Central Hospital, Tianjin 300450, China.
Tiantian LiDepartment of Pathophysiology, School of Basic Medical Science, Tianjin Medical University, Tianjin 300060, China.
Linchuang JiaDepartment of Pathophysiology, School of Basic Medical Science, Tianjin Medical University, Tianjin 300060, China.
Zhigang ZhaoTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Zhiqiang LiuTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Xiaozhi LiuTianjin Key Laboratory of Epigenetics for Organ Development in Preterm Infants, Tianjin Fifth Central Hospital, Tianjin 300450, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39619481
PMCPMC11605339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.